Pharmaceutical - Inflammatory diseases

Filter

Current filters:

Inflammatory diseases

Popular Filters

51 to 59 of 59 results

AstraZeneca collaborates with Amgen on five MAbs

03-04-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and Amgen (Nasdaq: AMGN), the world's largest independent…

AmgenAnti-Arthritics/RheumaticsAstraZenecaBiotechnologybrodalumabInflammatory diseasesLicensingPharmaceutical

GSK exercises option for Galapagos drug candidates

21-02-2012

Belgium-based Galapagos NV (Euronext: GLPG) says that its partner, UK pharma giant GlaxoSmithKline (LSE:…

Anti-Arthritics/RheumaticsBiotechnologyGalapagosGlaxoSmithKlineInflammatory diseasesLicensingPharmaceuticalResearch

Germany’s IQWiG finds no added benefit for Pfizer’s Xiapex

14-02-2012

In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products…

EuropeInflammatory diseasesPfizerPharmaceuticalRegulationXiapex

Merck buys in Exelixis’ PI3K-Delta program; returns product to Acumen

22-12-2011

California-based Exelixis (Nasdaq: EXEL) says it has granted US drug giant Merck & Co (NYSE: MRK) an…

Acumen PharmaceuticalsExelixisInflammatory diseasesLicensingMerck & CoNeurologicalOncologyPharmaceutical

BioLineRx inks deal with Compugen

14-12-2011

Israeli biopharma company BioLineRx (TASE: BLRX) has entered into a collaboration with fellow Israel-based…

BioLineRxBiotechnologyCardio-vascularCompugenInflammatory diseasesLicensingOncologyPharmaceuticalResearch

New start-up TopiVert gets $12.5 million funding

06-12-2011

UK investment group Imperial Innovations (AIM: IVO) and SV Life Sciences have committed to invest £8…

FinancialInflammatory diseasesJohnson & JohnsonPharmaceuticalResearchRespiVertTopiVert

Compugen links with DiscoveRx on novel peptide ligands for GPCR drug targets

01-12-2011

Israel’s Compugen (Nasdaq: CGEN) and USA-based DiscoveRx have entered into a partnership for the…

Cardio-vascularCompugenDiscoveRxInflammatory diseasesPharmaceuticalResearch

Mundipharma commits over $50 million in R&D funding for Infinity’s PI3K inhibitor

01-12-2011

Privately-held Mundipharma International as committed to providing over $50 million in funding in 2013…

FinancialInfinity PharmaceuticalsInflammatory diseasesLicensingMundi InternationalOncologyPharmaceuticalResearch

51 to 59 of 59 results

Back to top